Evidence map›Paper›PMID 32282833›Full record

ArticlePLoS pathogens2020

Killer cell proteases can target viral immediate-early proteins to control human cytomegalovirus infection in a noncytotoxic manner.

Liling Shan, Shuang Li, Jan Meeldijk, Bernadet Blijenberg, Astrid Hendriks, Karlijn J W M van Boxtel, Sara P H van den Berg, Ian J Groves, Martin Potts, Adriana Svrlanska and 3 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Liling ShanDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
Shuang LiDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID 0000-0001-8897-443X
Jan MeeldijkCenter for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
Bernadet BlijenbergDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
Astrid HendriksDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
Karlijn J W M van BoxtelDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
Sara P H van den BergDepartment of Medicine, University of Cambridge, Cambridge, United Kingdom.
Ian J GrovesDepartment of Medicine, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0001-8882-6701
Martin PottsDepartment of Medicine, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-6738-0066
Adriana SvrlanskaInstitute of Clinical and Molecular Virology, University of Erlangen-Nuremberg, Erlangen, Germany.ORCID 0000-0001-6062-9909
Thomas StammingerInstitute for Virology, Ulm University Medical Center, Ulm, Germany.ORCID 0000-0001-9878-3119
Mark R WillsDepartment of Medicine, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0001-8548-5729
Niels BovenschenDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID 0000-0002-8526-4456
University Medical Center Utrecht · NLUniversity of Cambridge · GBFriedrich-Alexander-Universität Erlangen-Nürnberg · DE

Funding

Medical Research Council MR/S00081X/1
6 · The paper itself

Abstract

Human cytomegalovirus (HCMV) is the most frequent viral cause of congenital defects and can trigger devastating disease in immune-suppressed patients. Cytotoxic lymphocytes (CD8+ T cells and NK cells) control HCMV infection by releasing interferon-γ and five granzymes (GrA, GrB, GrH, GrK, GrM), which are believed to kill infected host cells through cleavage of intracellular death substrates. However, it has recently been demonstrated that the in vivo killing capacity of cytotoxic T cells is limited and multiple T cell hits are required to kill a single virus-infected cell. This raises the question whether cytotoxic lymphocytes can use granzymes to control HCMV infection in a noncytotoxic manner. Here, we demonstrate that (primary) cytotoxic lymphocytes can block HCMV dissemination independent of host cell death, and interferon-α/β/γ. Prior to killing, cytotoxic lymphocytes induce the degradation of viral immediate-early (IE) proteins IE1 and IE2 in HCMV-infected cells. Intriguingly, both IE1 and/or IE2 are directly proteolyzed by all human granzymes, with GrB and GrM being most efficient. GrB and GrM cleave IE1 after Asp398 and Leu414, respectively, likely resulting in IE1 aberrant cellular localization, IE1 instability, and functional impairment of IE1 to interfere with the JAK-STAT signaling pathway. Furthermore, GrB and GrM cleave IE2 after Asp184 and Leu173, respectively, resulting in IE2 aberrant cellular localization and functional abolishment of IE2 to transactivate the HCMV UL112 early promoter. Taken together, our data indicate that cytotoxic lymphocytes can also employ noncytotoxic ways to control HCMV infection, which may be explained by granzyme-mediated targeting of indispensable viral proteins during lytic infection.

Indexed as

Amino Acid MotifsCytomegalovirusCytomegalovirus InfectionsGranzymesHost-Pathogen InteractionsHumansImmediate-Early ProteinsKiller Cells, NaturalProteolysisT-Lymphocytes, CytotoxicTrans-ActivatorsGranzymesIE1 protein, cytomegalovirusIE2 protein, CytomegalovirusImmediate-Early ProteinsTrans-Activators

Identifiers

PMID32282833
PMCPMC7179929
OpenAlexW3011997093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.